| May 20, 2025 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (Europe) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders (including Traumatic Cartilage Defect, Osteoarthritis, and Osteochondritis dissecans)
|
| April 9, 2025 |
Timely Disclosure Information
|
StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders Convening and Holding of Extraordinary General Meeting of Shareholders, and Reduction of Capital Stock (Capital Decrease)
|
| April 3, 2025 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Traumatic articular Cartilage Deficiency Syndrome, Osteoarthritis, and Osteochondritis dissecans
|
| April 2, 2025 |
Timely Disclosure Information
|
StemRIM Announces the Interim Analysis Results for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke
|
| March 3, 2025 |
Timely Disclosure Information
|
StemRIM Announces the Protocol Amendment for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke
|
| January 15, 2025 |
Timely Disclosure Information
|
StemRIM Announces the Extension of the Term for the Tripartite Joint Research Agreement Aimed at Elucidating Skin Anti-Aging Mechanisms
|
| December 23, 2024 |
Timely Disclosure Information
|
StemRIM Announces the First Administration of Phase 2 Clinical Trial for Redasemtide Targeting Ischemic Cardiomyopathy
|
| December 12, 2024 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Selection for the AMED Project “FY2024 Project for Fundamental Technology Development toward Industrialization of Regenerative Medicine and Gene Therapy”
|
| December 11, 2024 |
Timely Disclosure Information
|
StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation
|
| December 9, 2024 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (Europe) for the Use of the HMGB1 Fragment Peptide Redasemtide as an Additional Therapeutic Indication for Cardiomyopathy and Chronic Heart Failure Caused Thereby
|
| December 5, 2024 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration in Australia for Peptides Related to the HMGB1 Fragment Peptide Redasemtide
|
| November 13, 2024 |
Timely Disclosure Information
|
StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock
|
| November 5, 2024 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration in Japan for the HMGB1 Peptide Redasemtide
|
| October 31, 2024 |
Timely Disclosure Information
|
Presentation Material for Business Plan and Growth Potential
|
| September 25, 2024 |
Timely Disclosure Information
|
StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers Employees and External Collaborators
|
